State of New Jersey Common Pension Fund D’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.39M Sell
35,600
-1,099
-3% -$35.5K ﹤0.01% 1321
2026
Q1
$1.19M Sell
36,699
-20,421
-36% -$656K ﹤0.01% 1388
2025
Q4
$2.01M Sell
57,120
-25,774
-31% -$913K 0.01% 1317
2025
Q3
$2.18M Buy
82,894
+14,973
+22% +$447K 0.01% 1106
2025
Q2
$1.8M Buy
67,921
+1,671
+3% +$44K 0.01% 1366
2025
Q1
$1.6M Buy
66,250
+25,497
+63% +$806K 0.01% 1393
2024
Q4
$1.64M Buy
40,753
+3,192
+8% +$182K 0.01% 1491
2024
Q3
$2.38M Hold
37,561
0.01% 888
2024
Q2
$1.99M Sell
37,561
-34,895
-48% -$2.29M 0.01% 1020
2024
Q1
$5.94M Buy
+72,456
New +$3.22M 0.02% 646
2023
Q3
Sell
-109,100
Closed -$1.77M 1666
2023
Q2
$1.77M Buy
+109,100
New +$2.29M 0.01% 1567

Other funds holding VKTX

State of New Jersey Common Pension Fund D's VKTX Position: Q2 2026 in Review

State of New Jersey Common Pension Fund D reduced its Viking Therapeutics (VKTX) stake by 3% in Q2 2026, selling an estimated $35.5K and leaving 35,600 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

State of New Jersey Common Pension Fund D first reported a position in VKTX in Q2 2023 and has held it in 11 quarters since. The position peaked at $5.94M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • State of New Jersey Common Pension Fund D held 35,600 shares of Viking Therapeutics worth $1.39M as of Q2 2026.
  • State of New Jersey Common Pension Fund D sold 1,099 Viking Therapeutics shares in Q2 2026, an estimated $35.5K.
  • Viking Therapeutics made up ﹤0.01% of State of New Jersey Common Pension Fund D's portfolio in Q2 2026, its #1321 holding.
  • State of New Jersey Common Pension Fund D first reported a position in Viking Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • State of New Jersey Common Pension Fund D's Viking Therapeutics position peaked at $5.94M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on State of New Jersey Common Pension Fund D's 13F filing for Q2 2026, filed 4 Aug 2026.